MYGN: Myriad Genetics, Inc.
Performance
MYGN -8.89%
Watchlist
Select an item
Summary
MYGN at a glance
MYGN returned -8.89% over the past year and -28.44% a year over five years. Its worst drop in that year was -63.84%, smaller than 10% of stocks on Redstone, and its Sharpe ratio of 0.32 beats 42% of stocks on Redstone. It pays no dividends.
Current Drawdown
-27.43%
Rolling Volatility
125.92%
Actions
Metrics
Risk Indicators
Alpha19.81%
Beta0.74x
Sharpe0.32
Sortino0.43
Omega1.07
Calmar-0.14
Martin0.69
Profile
About MYGN
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights.
- Sector
- Health Care
- Industry
- In Vitro & in Vivo Diagnostic Substances
- Market cap
- $549M
- Listed
- Oct 1995
- Employees
- 2,700
- Headquarters
- Salt Lake City, UT
- Website
- myriad.com
Comparisons